Netherlands· NL-06b15ba3833b

Ambrisentan Accord 10 mg, filmomhulde tabletten

A ambrisentan product containing ambrisentan, registered in Netherlands by Accord Healthcare B.V.. The same ATC class is registered in 18 of our 19 countries.

ATC C02KX02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ambrisentanAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ambrisentan is registered in 18 of 19 countries.

Countries holding a registration under ATC C02KX02 (ambrisentan), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search ambrisentan products by name

Ambrisentan · ATC C02KX02

18 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ambrisentan costs, country by country.

Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Ambrisentan · price per daily dose (7.5 mg)

USD · FX 28 Sept 2026

CH Switzerland$54.19

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: AMBRISENTAN
Manufacturer: Accord Healthcare B.V.
Country: Netherlands (NL)
ATC code: C02KX02
ATC class: Ambrisentan
Defined daily dose: 7.5 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
123166

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

155 interactions on record for ambrisentan.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ambrisentan against other medicines How interaction checks work

Ambrisentan · interactions on record

155 records

5 severe
71 moderate
12 minor
67 info

Most severe, free to view

LeflunomidL04AA13severe
TeriflunomidL04AA31severe
CiclosporinL04AD01severe
LeflunomideL04AK01severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ambrisentan in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ambrisentan products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

Austria · Ambrisentan Accord, Ambrisentan Aop
Belgium · Ambrisentan Accord, Ambrisentan Sandoz
Bulgaria · Aмбрисентан Aкорд, Амбрисентан Зентива
Cyprus · Ambrisentan Msn, Ambrisentan Sapiens
Czechia · Ambrisentan Accord, Ambrisentan Sandoz
Germany · Ambripuren, Ambrisentan
Denmark · Ambrisentan "sandoz", Ambrisentan Accord
Estonia · Ambrisentan Inteli, Ambrisentan Norameda
Spain · Ambrisentan Accord, Ambrisentán Aurovitas
Finland · Ambrisentan Accord
France · Ambrisentan Accord, Ambrisentan Arrow
United Kingdom (Northern Ireland) · Ambrisentan Accord, Ambrisentan Axunio
Greece · Ambicipen, Ambrisentan Accord
Croatia · Ambrisentan Accord
Hungary · Ambrisentan Azr
Ireland · Ambrisentan Accord
Iceland · Ambrisentan Viatris, Volibris
Italy · Ambrisentan Accord, Ambrisentan Medac
Liechtenstein · Ambrisentan Viatris, Volibris
Lithuania · Ambrisentan Aop, Ambrisentan Inteli
Latvia · Ambrisentan Inteli, Ambrisentan Norameda
Norway · Ambrisentan Accord, Ambrisentan Viatris
Portugal · Ambrisentano Accord, Ambrisentano Generis
Sweden · Ambrisentan Accord, Ambrisentan Bluefish
Slovenia · Ambrisentan Accord
Slovakia · Ambrisentan Aop

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/0fca01c8-13f5-4971-ac31-140b4b29ea72
GET /v1/drugs/0fca01c8-13f5-4971-ac31-140b4b29ea72?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h123166_smpc.pdf",
  "strength": null,
  "atc_label": "Ambrisentan",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg123166",
  "excipients": [
    "ALLURAROOD AC ALUMINIUM LAK (E 129)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "LACTOSE 1-WATER",
    "LECITHINE, SOYA (E 322)",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "AMBRISENTAN"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h123166.pdf",
  "authorised_at": "2019/11/06",
  "procedure_number": "DE/H/5625/002",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "123166",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about ambrisentan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console